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Abstract
Introduction and hypothesis—To estimate the risk of repeat surgery for recurrent prolapse or
mesh removal after vaginal mesh versus native tissue repair for anterior vaginal wall prolapse.
Methods—We utilized longitudinal, adjudicated, healthcare claims from 2005 to 2010 to identify
women ≥18 years who underwent an anterior colporrhaphy (CPT 57420) with or without
concurrent vaginal mesh (CPT 57267). The primary outcome was repeat surgery for anterior or
apical prolapse or for mesh removal/revision; these outcomes were also analyzed separately. We
utilized Kaplan–Meier curves to estimate the cumulative risk of each outcome after vaginal mesh
versus native tissue repair. Cox proportional hazards models were used to estimate the hazard ratio
(HR) for vaginal mesh versus native tissue repair, adjusted for age, concurrent hysterectomy, and
concurrent or recent sling.
Results—We identified 27,809 anterior prolapse surgeries with 49,658 person-years of follow-
up. Of those, 6,871 (24.7%) included vaginal mesh. The 5-year cumulative risk of any repeat
surgery was significantly higher for vaginal mesh versus native tissue (15.2 % vs 9.8 %,
p<0.0001) with a 5-year risk of mesh revision/removal of 5.9%. The 5-year risk of surgery for
recurrent prolapse was similar between vaginal mesh and native tissue groups (10.4 % vs 9.3 %,
p=0.70. The results of the adjusted Cox model were similar (HR 0.93, 95%CI: 0.83, 1.05).
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Conclusions—The use of mesh for anterior prolapse was associated with an increased risk of
any repeat surgery, which was driven by surgery for mesh removal. Native tissue and vaginal
mesh surgery had similar 5-year risks for surgery for recurrent prolapse.
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Introduction
The recent US Food and Drug Administration (FDA) safety communication on serious
complications from transvaginal mesh [1] heightened awareness of graft augmentation in
pelvic organ prolapse procedures among healthcare providers, patients, and the general
public [2]. The FDA highlighted complications due to surgical mesh devices such as mesh
exposure/extrusion, vaginal scarring/shrinkage, pain, dyspareunia, infection, and organ
perforation, as well as the repeat surgeries associated with these complications [3]. A
rationale for synthetic mesh augmentation was to address the risk of recurrent prolapse after
surgical repair, which has been reported to be as high as 29 % [4]. However, the literature
suggests that long-term outcomes with vaginal mesh augmentation may not be better than
those with native tissue, especially for surgeries in the apical and posterior compartment of
the vagina [3].
Prolapse in the anterior compartment is particularly challenging as the short-term recurrence
after anterior colporrhaphy is relatively high [5–8]. Randomized trials of native tissue repair
versus mesh augmentation have shown that anatomical cure is higher for mesh procedures
[5, 6, 9], and the FDA supports this claim in their systematic review [3]. However, the FDA
also noted that “this anatomic benefit may not result in superior symptomatic outcomes or
lower rates of repeat surgery for recurrent prolapse” compared with traditional native tissue
repair without mesh [1, 3]. Furthermore, the use of synthetic mesh may be associated with
mesh complications, which may require additional interventions and surgical repair. A major
limitation of the existing literature is that the cohorts studied were relatively small and the
length of follow-up was relatively short. In addition, limited data exist regarding the rate of
repeat surgery for recurrent prolapse or mesh complications.
Healthcare claims data of commercially insured patients may provide particularly useful
information to address this timely and controversial issue, since a large cohort of women can
be evaluated with longer-term follow-up. Furthermore, limitations due to loss to follow-up
in trials may be mitigated as these data are based on insurance claims. Thus, the objective of
this study was to utilize a large, population-based database to estimate the rate of repeat
surgery after vaginal mesh versus native tissue repair for anterior vaginal wall prolapse. We
also sought to estimate the rates of repeat surgeries due to recurrent prolapse versus mesh
complications and to assess predictors of repeat surgery.
Materials and methods
Data source
For this analysis, we utilized 6 years of data (2005–2010) from the MarketScan®
Commercial Claims and Encounters (CC&E) database and Medicare Supplemental and
Coordination of Benefits database (copyright © 2011 Thomson Healthcare Incorporated Inc.
All rights reserved) [10]. The available data included adjudicated, paid healthcare claims for
approximately 28.3 million individuals in 2005, increasing to 48.8 million in 2010.
Contributing individuals included those with commercial, employment-based insurance,
such as employees, their spouses, dependants, as well as retirees. Of note, in 2010, 55.3 % of
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the US population, or 170.7 million individuals, had employment-based insurance [11].
These de-identified, individual-level inpatient and out-patient claims were aggregated from
approximately 100 payers in the United States. Claims and enrollment data were validated
by Thomson Reuters to ensure completeness, accuracy, and reliability. Although the data
were anonymized, unique individuals can be followed over time using encrypted
identification numbers, and detailed enrollment data ensured that only those individuals who
could generate a claim were considered as part of the population at risk at any given time.
This study was determined to be exempt from further review by the Institutional Review
Board at the University of North Carolina at Chapel Hill.
Inclusion criteria and index surgery
The population at risk included all women aged 18 years and older from 2005 to 2010.
Among these women, our goal was to compare women who underwent a native tissue
anterior colporrhaphy with those who had an anterior colporrhaphy with mesh
augmentation, or vaginal mesh. We identified anterior colporrhaphies based on current
procedural terminology (CPT) code 57240 (Table 1). If CPT 57267 (insertion of mesh or
other prosthesis for repair of a pelvic floor defect, each site [anterior, posterior
compartment], vaginal approach) was present, we counted these surgeries as a vaginal mesh
procedures. If CPT 57267 was not present, these surgeries were counted as a native tissue
repairs.
In order to assess baseline covariates, including recent urogynecological procedures, we
excluded women who did not have at least 6 months of continuous enrollment prior to the
first, or index, procedure. We also excluded women who had mesh placed during the
baseline period, in order to limit misclassification of our primary exposure, vaginal mesh,
and to enable us to attribute future surgery for mesh complications to the index procedure
and not prior surgeries. Based on this same rationale, we also excluded women with a prior
abdominal or laparoscopic sacrocolpopexy. Similarly, if a procedure to remove or revise
mesh (CPT codes 57415, 57426, 57295, and 57296) was performed prior to the index
surgery, those women were also excluded (Table 1).
Because the code for mesh insertion, CPT 57267, is not linked to a specific procedure and
we wanted to specifically estimate the impact of mesh augmentation for anterior
colporrhaphy, we excluded women with other concomitant prolapse procedures, including
posterior colporrhaphy (Table 1). For example, if CPT 57267 is listed along with CPT
57260 for an anterior and posterior colporrhaphy, it is impossible to determine if the mesh
was placed in the anterior or posterior compartment. Thus, the only way to ensure that mesh
was placed in the anterior compartment was to exclude women who underwent other
prolapse procedures. Although we excluded concurrent prolapse procedures based on CPT
codes (Table 1), we did not exclude concurrent hysterectomy or concurrent sling. Because a
sling may also have an impact on the risk of recurrent prolapse, we included both a
concurrent sling and any recent sling in the prior 6 months in our definition of a sling
procedure.
Repeat surgery
After the initial anterior colporrhaphy, either with native tissue or vaginal mesh, we
identified any repeat surgery for either recurrent anterior or apical prolapse, or a mesh
complication. We defined repeat surgery for recurrent prolapse based on subsequent
procedures for anterior prolapse (CPT codes 57240, 57260, 57265, 57284, 57285, 57423) or
for apical prolapse (CPT codes 57280, 57282, 57283, 57425). Our rationale for including
both anterior and apical procedures was that surgeons may opt for either an anterior and/or
apical procedure to manage short-term recurrent anterior vaginal wall prolapse. We defined
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surgery for mesh complications based on the following CPT codes: 57415 removal of
vaginal foreign body, 57426 revision/removal of vaginal prosthetic graft laparoscopy, 57295
revise vaginal graft via vaginal approach, and 57296 revise vaginal graft via abdominal
approach. It is important to note that repeat surgeries for recurrent prolapse and for mesh
complications were not mutually exclusive. In addition, if a surgery for a mesh complication
occurred prior to a surgery for recurrent prolapse, we opted to censor individuals at the time
of the mesh surgery for the analysis of recurrent prolapse. Similarly, in the analysis for mesh
complications, we censored individuals who underwent surgery for recurrent prolapse if it
occurred prior to the mesh complication.
For surgery for mesh complications, we evaluated this outcome in both the native tissue and
the vaginal mesh cohorts, even though mesh complications should not occur in those
undergoing a native tissue repair. It is possible that a mesh complication could occur in the
“native tissue” cohort if the patient had mesh placed before the baseline period (more than 6
months prior to the index procedure) or if a midurethral sling resulted in a sling revision/
removal due to a mesh complication that was not coded using the typical CPT code for sling
revision/removal.
Statistical analysis
Using Kaplan–Meier survival curves, we estimated the cumulative risk of repeat surgery for
recurrent prolapse or mesh complications overall, and for each outcome separately at yearly
intervals. We also estimated the cumulative risk at 2-year follow-up for specific subgroups
based on age, calendar year of the index procedure, concomitant or recent sling, and
concomitant hysterectomy.
In order to adjust for differences in age, concomitant hysterectomy, or concomitant/recent
sling between patients receiving native tissue and those receiving vaginal mesh, we
estimated adjusted hazard ratios (HR) using Cox proportional hazards model. We included
age as a six-level categorical variable (18–34, 35–44, 45–54, 55–64, 65–74, 75+). Wald Chi-
squared statistics were used to test the significance of independent predictors with a two-
sided alpha = 0.05. Analyses were performed using SAS, v9.2 (SAS Institute, Cary, NC,
USA).
Results
We identified 27,809 anterior prolapse surgeries with 49,658 person-years of follow-up
among women aged ≥ 18 years. Of these, 20,938 (75.3 %) were native tissue repairs while
6,871 (24.7 %) included vaginal mesh. Women who underwent native tissue repair were
younger (median 55 years, interquartile range (IQR) 47, 63) compared with the vaginal
mesh surgery (median 59 years, IQR 52, 67, p< 0.0001); Table 2). The median duration of
follow-up was similar in those receiving native tissue (1.3 years [IQR 0.5, 2.7]) and vaginal
mesh (1.4 years [IQR 0.5, 2.7], p=0.44). When evaluating the calendar year in which the
index surgery was performed, there were differences between groups with an increase in the
proportion of procedures involving vaginal mesh from 2005 to 2010 (p<0.0001). Fewer
native tissue repairs had a concomitant or recent sling (62.4 % vs 70.6 %, p<0.0001, but a
higher proportion underwent a concurrent hysterectomy (38.3 % vs 18.4 %, p<0.0001; Table
2).
When we estimated the risk of any repeat surgery after the index surgery for anterior
prolapse, the 5-year cumulative risk was significantly higher for vaginal mesh (15.2 % vs
9.8 %, p<0.0001). However, the 5-year cumulative risk of recurrent prolapse surgery was
similar in the two groups (native tissue: 9.3 % [95%CI 8.6, 10.0]; vaginal mesh: 10.4 %
[95%CI 8.8, 12.1] p=0.70; Table 3). The difference in the risk of any repeat surgery was due
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to the significantly higher 5-year risk of mesh complication in the vaginal mesh group (5.9
% [95%CI 5.0, 6.9] compared with native tissue (0.7 % [95%CI 0.5, 0.9], p<0.0001).
In order to further evaluate the impact of age, year of index surgery, and concurrent
hysterectomy or sling, we estimated the 2-year cumulative risks of repeat surgery for
recurrent prolapse and mesh complications in these subgroups of patients. These 2-year
estimates are shown in Table 4 as absolute risks with 95%CI. Age at index surgery or year
of the index surgery did not yield a definitive trend for surgery for recurrent prolapse at 2
years post-operatively for either the native tissue or the vaginal mesh cohorts. However,
concurrent hysterectomy decreased the risk of surgery for recurrent prolapse in the native
tissue group (4.4 % [95 % CI 3.9, 4.9] versus 7.8 % [95%CI 7.3, 8.4]) and recent/concurrent
sling decreased surgery for recurrent prolapse in both groups (Table 4).
Surgery for a mesh complication was primarily pertinent to the vaginal mesh cohort. There
was no consistent trend for mesh surgery based on age, concurrent hysterectomy or recent/
concurrent sling. However, the 2-year risk of mesh surgery increased from 2.6 % (95 % CI
0.9, 4.3) in 2005 to 4.8 % (95%CI 3.6, 6.0) in 2008.
We evaluated the risk of any repeat surgery as well as surgery for recurrent prolapse and a
mesh complication using Cox proportional hazards models adjusted for age, concurrent
hysterectomy, and concurrent or recent sling. Vaginal mesh was associated with an increase
in the risk of any repeat surgery compared with native tissue (HR 1.33, 95%CI 1.20, 1.46).
The risk of surgery for recurrent prolapse was similar in those with vaginal mesh versus
native tissue (HR 0.93, 95%CI 0.83, 1.05). Thus, the difference in the rate of repeat
surgeries was driven by mesh complications (HR 8.21, 95%CI 6.31, 10.67).
Discussion
In this population-based cohort of 27,809 vaginal procedures for anterior vaginal wall
prolapse, the 5-year cumulative risk of repeat surgery was higher for vaginal mesh
procedures (15.2 %) than for native tissue surgeries (9.8 %), which was due to subsequent
surgeries for mesh removal and not for recurrent prolapse. These estimates are useful in
counseling patients regarding the need for reoperation after prolapse surgery.
The 2011 FDA update regarding transvaginal mesh reported that mesh augmentation may
provide anatomical benefit in the anterior compartment, but with no improvement in the
quality of life [1]. This claim was supported by the initial reports of several randomized
trials that found that prolapse procedures utilizing mesh had a lower risk of recurrent
prolapse [5, 6, 9, 12, 13]. Systematic reviews and meta-analyses also supported this
conclusion [7, 8, 14, 15]. However, limitations of these existing trials included a non-
blinded evaluator [3] and a relatively short follow-up of 12 months [5, 9, 13, 16–18].
Furthermore, there was some evidence that any improvement in anatomical outcomes from
the use of mesh was of little benefit to the patient, since the few studies that assessed
patient-centered outcomes, such as quality of life, failed to show a difference between native
tissue and mesh augmentation procedures [12, 14, 17].
While the risk of anatomical recurrence may be lower with mesh augmentation in the
anterior compartment, a critical question is whether mesh decreases the need for reoperation
for recurrent prolapse. Nieminen et al. reported that 18 % (17 out of 96) in the native tissue
and 11 % (11 out of 104) in the mesh group were referred for reoperation for either recurrent
prolapse or urinary incontinence by 3 years, a difference that was not statistically significant
[6]. In our study, we found that the risk of repeat surgery for prolapse was comparable at 9.3
% for native tissue versus 10.4 % for vaginal mesh by 5 years. Adjusting for differences in
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age and other concurrent pelvic organ procedures (hysterectomy and sling) did not
meaningfully alter the observed association.
In our analysis, the driving factor for a higher risk of reoperation after mesh augmentation
was the need for surgery for a mesh complication. Randomized trials have reported a risk of
mesh exposure/extrusion that ranges from 5 % to 19 % [6, 9, 12, 17, 18]. However, some of
these mesh exposures/extrusions were managed conservatively, and the proportion of
subjects undergoing reoperation in an operating room for mesh complications was
approximately 3.2 % to 7.6 % [5, 6, 12, 13]. In an analysis of over 800 prolapse procedures
using implanted grafts or mesh, Nguyen et al. reported that the reoperation risk for vaginal
mesh exposure was 3.4 % during a 21-month period [19]. These data were comparable to
estimates in this report of 3.0 % risk of mesh exposure surgery at 1 year, increasing to 5.9 %
at 5 years.
We analyzed predictors of future surgery and found that concurrent hysterectomy and
recent/concurrent sling decreased the risk of surgery for recurrent anterior and/or apical
prolapse. One explanation is that if uterine prolapse was present, a hysterectomy decreased
persistent or recurrent prolapse in the apical compartment. A prior or concurrent sling may
also decrease future anterior prolapse given the supportive nature of a sling in the distal
anterior compartment. Regarding predictors for surgery for mesh complications, we found
that the risk of reoperation was lower for surgeries performed in 2005 and that this risk
increased each subsequent year. It is possible that more recently available mesh materials
and/or kits may be associated with a higher risk of mesh complications. Another possibility
is that less experienced providers began to perform these procedures and had higher
complication rates.
The strengths of this study were based in the inherent characteristics of a large, population-
based database, which allowed us to evaluate over 20,000 native tissue and 6,800 vaginal
mesh procedures for anterior vaginal wall prolapse. These healthcare claims data allowed us
to follow patients over time, even if they did not return to their primary surgeon or the
hospital of their index surgery for their reoperation. This was an important issue because
patients with a complication may seek care from another surgeon at a different institution.
Insurance claims data enabled us to capture any reoperations, as long as a patient remained
insured. By utilizing data from 2005 to 2010, we were able to provide 5-year cumulative
risks, which is significantly longer than the follow-up periods of existing studies.
This study was limited by constraints inherent in the database. This database represents
those with health insurance, and thus, the results may not be generalizable to an uninsured
population. In addition, data regarding race, physical examination findings, such as body
mass index and severity of prolapse, medical history and surgical data were not available,
and we were unable to evaluate the impact of these variables on our outcomes. Because we
did not have all of the baseline characteristics of the study population, it was possible that a
higher proportion of women who underwent vaginal mesh repair had recurrent or more
severe prolapse compared with women in the native tissue group. However, given the fact
that ~75,000 vaginal mesh procedures were performed in 2010 [3], it was unlikely that mesh
was only utilized in women with recurrent prolapse.
As with any secondary data analysis, misclassification may have existed. For example, a
small number of women in the native tissue group had mesh complications. We suspect that
these women had mesh placed prior to the baseline period and/or had a different type of
procedure that involved mesh, such as a sling. Another limitation was that we cannot
determine the specific mesh or mesh kit/procedure that was performed, and therefore cannot
comment on whether different mesh procedures carry different risks of complications.
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Because of limitations imposed by the CPT coding system, which was central to our
database, we were forced to exclude certain women from our analysis, in order to limit
misclassification of our treatment groups to the greatest extent possible, and to define a more
homogeneous cohort, overall, in which the effect of mesh could be evaluated. We have no
reason to believe, however, that these a priori exclusions affected either study group
preferentially.
Despite these limitations, our study provided insight into the longer-term risk of surgical
intervention for recurrent prolapse and mesh complications after native tissue versus vaginal
mesh for anterior vaginal wall prolapse. These estimates are valuable in counseling patients
regarding what they can anticipate for reoperation rates for recurrent pro-lapse and/or mesh
complications. Our results clearly indicated that patients seeking to minimize the risk of
future surgery should carefully consider mesh augmentation of the anterior compartment,
since the overall risk of future surgery was actually higher in the women receiving mesh.
Furthermore, the rate of surgery for recurrent prolapse was no different with or without
mesh. Lastly, our findings emphasize the importance of prospective, comprehensive, and
long-term assessments of the safety and effectiveness of transvaginal mesh for pelvic organ
prolapse.
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Table 2
Characteristics of women aged ≥ 18 undergoing vaginal mesh versus native tissue repair for anterior vaginal
wall prolapse from 2005 to 2010
Native tissue (n=20,938) Vaginal mesh (n=6,871) p value
Age
 Median (years) 55 (IQR 47, 63) 59 (IQR 52, 67) <0.0001
 Range (years) 19–93 22–95
Age
 18–34 668 (3.2) 84 (1.2)
 35–44 3,262 (15.6) 593 (8.6)
 45–54 6,027 (28.8) 1,591 (23.2)
 55–64 6,594 (31.5) 2,503 (36.4)
 65–74 2,784 (13.3) 1,262 (18.4)
 75+ 1,603 (7.7) 838 (12.2)
Follow-up time
 Median (years) 1.3 (IQR 0.5, 2.7) 1.4 (IQR 0.5, 2.7) 0.44
Calendar year
 2005 3,214 (15.4) 563 (8.2) <0.0001
 2006 2,968 (14.2) 923 (13.4)
 2007 3,145 (15.0) 1,175 (17.1)
 2008 3,652 (17.4) 1,497 (21.8)
 2009 4,197 (20.0) 1.424 (20.7)
 2010 3,762 (18.0) 1,289 (18.8)
Concomitant surgeries
 Recent/concurrent sling 13,061 (62.4) 4,849 (70.6) <0.0001
 Concurrent hysterectomy 8,018 (38.3) 1,263 (18.4) <0.0001
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